Introduction
The global prevalence of Helicobacter pylori infection is more than 50%, and it may vary significantly within and between countries. [1, 2] H. pylori prevalence in Sri Lanka has been reported to be as high as 70%. [3] Its severe pathological manifestations and difficulty in culture, results in the use of empirical antibiotics for treatment. Thus, it is of paramount importance to determine the antibiotic resistance of H. pylori in Sri Lanka.
Clarithromycin is one of the key antibiotics used for the treatment [4] of H. pylori. Clarithromycin resistance is increasing worldwide (the primary resistance rate is obtained (Female-43 and Male-33) during the endoscopy procedure from antrum/ulcer lesion into normal saline. Laborotory investigations were done at the Department of Microbiology and the Department of Pathology, in a state university, Sri Lanka.
The proportion of H. pylori in gastric biopsies were determined by using an in-house biopsy urease test. [10] The samples which were positive for the in-house urease test within 12 hours were used for deoxyribonucleic acid (DNA) extraction by QIAamp DNA mini kit (Qiagen, Germany) following the manufacturer's instructions. The extracted DNA was amplified by PCR using primers targetting glmM (ureC) gene [11] for identification of H. pylori and fragment of the peptidyltransferase region of the 23S ribosomal ribonucleic acid (rRNA) gene [8] of H. pylori for mutation detection [ Table 1 ]. The urease test-positive samples were further confirmed for H. pylori infection by histopathology (Haematoxylin and Eosin staining) prior to Helicobacter-specific PCR.
Clarithromycin resistance of H. pylori was determined by PCR-restriction fragment length polymerphism (RFLP). All PCRs were performed in 0.2-ml tubes using a Flexigene thermal cycler (version 31.04). The 50 μl PCR reaction mixture consisted of PCR buffer (5 μl) supplemented with 2 mM MgCl 2 (Go Taq Flexi DNA polymerase kit; Promega), 0.2 mM each dATP, dCTP, dGTP and dTTP (1 μl; Promega), 0.5 μM each primer (Integrated DNA Technologies), 1.25U of Go Taq Flexi DNA polymerase (promega) and 2 μl of nucleic acid (~20 ng). Optimized PCR conditions for glmM gene amplified were denaturation at 93°C for 5 min, PCR cycle at 93°C for 1 min, 55°C for 1 min and 72°C for 1 min, PCR was performed for 40 cycles with a final extension at 72°C for 5 min. PCR parameters for 23S rRNA included an initial 5 min denaturation at 94°C. The PCR cycles consisted of 94°C for 1 min, 58°C for 1 min and 72°C for 1 min, with a final extension at 72°C for 5 min. PCR products were visualized in a 1.5% agarose gel and resulted in a 294 base pair product for glmM gene and 1400 bp product for 23SrRNA gene [ Figure 1 ].
Restriction enzymes MboII (Thermo Scientific, USA) and Bsa I (New England Biolabs, Mass, USA) were used in separate reactions to digest the 23SrRNA PCR products. The amplicon was digested with 2.5U of Mbo II at 37°C for 16 hours and the restriction products were analyzed on a 2% agarose gel. Mutation at A2142G was detected by the cleavage of the 1400bp amplicon resulting in a single 700bp band in the gel. In the wild type, no digestion was detected.
Mutation A2143G was detected by digesting the amplicon with Bsa 1 restriction enzyme in the following conditions. Bsa I (2.5U) was digested with the amplicon of 23S rRNA gene at 37°C for 16 hours. Mutation A2143G was detected by the cleavage of the 1400 bp amplicon resulting in three bands at 700 bp, 400 bp and 300 bp in the gel. In the wild type, restriction digestion resulted in two bands at 1000 bp and 400 bp in the gel [ Figure 2 ].
Statistical analyses were done with Chi-square test using the Statistical Package of Social Sciences (SPSS) (version 16; SPSS, Inc., Chicago, Illinois, USA).
Ethical approval was granted by ethical review committee, at the state university (No: 723/13).
Results
Among the dyspeptic patients, 43 (57%) were female while 33 (43%) were male. Median age was 50 years. Endoscopic examination identified the disease as antral gastritis in 53/76 (70%), gastric ulcer disease in 9/76 (12%), pangastritis in 8/76 (10%) and duodinitis in 6/76 (8%) patients. Ten 10/53 (19%) patients who were identified as suffering from antral gastritis was positive for H. pylori by in-house campylobacter like organism (CLO) test while 1/10 (11%) among gastric ulcer patients, 3/8 (38%) of pangastritis patients and 2/6 (33%) among duodinitis patients were also positive for H. pylori by this test. These samples were positive for H. pylori by the in-house CLO test with in 12 hours of incubation. Of the 16 urease-positive H. pylori infection was more common among females 10/15 (67%) and in the age-group of < 50, 9/15 (60%). A high frequency of infection was also observed among Sinhalese, 11/15 (73%), and there was a statistically significant relationship between ethnicity and presence of H. pylori (P = 0.023). The highest frequency of H. pylori infection was noted in families with 3 to 5 members [n = 10/15 (67%)]. However, no association was observed between presence of H. pylori with patient age, gender, family dimension and type of consumed water [ Table 2 ].
Discussion
In Sri Lanka, clinically suspected H. pylori infections are treated with a proton pump inhibitor combined with two antibiotics which included clarithryomycin as a compulsory drug. Unfortunately, this treatment is not tailor made to Sri Lanka since screening for clarithyromyin resistance is not done. Some of the other countries screen the patients for clarithyromyin resistance to H. pylori prior to treatment.
The rate of A2142G mutation associated with resistance to clarithromycin was found to be very high in Sri Lanka. The proportion of H. pylori infection among the dyspeptic patients was found to be decreasing (20%) which is in line with the current global trend of decreasing prevalence. [12, 13] However, in Sri Lanka, the finding of high A2142G mutation is alarming. Published studies showed that although A2142G mutation is present it sometimes may not be phenotypically expressed. [14] The eradication of H. pylori from patients following treatment is a good indicator to detect the expression of clarithromycin resistance gene [15] and which can be practically done by detecting H. pylori antigen in stool and will be done in the future. Therefore, currently, we cannot conclude the efficacy of clarithromycin in the treatment of H. pylori in Sri Lanka.
The countries with low clarithromycin resistance are recommended the standard clarithromycin containing triple therapy, whereas the other countries use a tailor made treatment for a better outcome. According to some investigators, A2142G mutation site was less common when compared to A2143G mutation. [16] Whereas in some countries, both A2142G and A2143G mutations of H. pylori were found to occur in equal frequency. [17] Our findings were in line with the results of other developing countries such as Iran and Korea where they have encountered A2142G mutation as the most common mutation. [18, 19] In our study, A2143G mutation was not detected. Further presence of H. pylori was significantly associated with ethnicity which may be due to food habits and cultural practices. Simultaneously, clarithromycin resistance was also significantly associated to ethnicity. There may be certain factors associated to ethic groups which may predispose to development of antibiotic resistance. The clinical significance of this matter cannot be discussed further Different studies done in different geographic populations have showed high clarithromycin resistance with either one of the A2142G/A2143G mutations, thus is not a finding specific to this study. Raymond et al. [20] in 2007 had found a 90% prevalence of A2143G mutation, while Abdollahi et al., [18] in 2011 had shown a 55% prevalence of A2142G mutation, whereas Kim KS et al. [19] in 2002 had reported 100% mutation in A2143G or T2182C sites in Korea. Studies have shown that phenotypic and genotypic expressions of clarithromycin resistance do not correlate. [14] In a study by Vincenzo De Francesco et al., [14] it was shown that clarithromycin phenotypic resistance was significantly lower as compared with genotypic resistance (18.4% versus 37.6%).
The current results indicate the importance of determination of the eradication efficacy of H. pylori following clarithromycin treatment which can give an insight regarding the phenotypical expression of the A2142G mutation in Sri Lanka. If the mutation is phenotypically expressed screening for resistance prior to initiation of treatment may be required in the future.
Conclusion
This study documented for the first time a high proportion of A2142G mutation associated with clarithromycin resistance in H. pylori among dyspeptic patients in Sri Lanka.
